Using xenotransplant models of diffuse large B-cell lymphoma (DLBCL), our group has explored over the years MRS-detectable changes induced by multi-agent chemotherapy: CHOP [12], CHOP and rituximab (R-CHOP) immunochemotherapy [36], radiation therapy [37], and therapy with mTORC1 inhibitor [38]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.